Indoco Remedies DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.70×	0.93×	1.05×	0.71×	0.74×
	1.30×	−6.94×	5.10×	0.89×	0.89×
	1.8%	0.8%	−0.9%	8.4%	12.9%
	0.73×	0.73×	0.73×	0.96×	1.27×
	2.57×	2.78×	2.39×	1.93×	1.61×
	3.1%	−10.9%	−8.2%	9.9%	17.5%
	−9.7%	−9.7%	−6.9%	9.2%	13.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDOCO₹209.50

Indoco Remedies Limited

· Pharma & Health

₹ CrorePeersSAIPARENT PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹1,934 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.71	1.05	0.93	0.70
Interest Burden (Pretax/EBIT) ×	0.89	0.89	5.10	-6.94	1.30
EBIT Margin %	12.91	8.39	-0.88	0.83	1.84
Asset Turnover ×	1.27	0.96	0.73	0.73	0.73
Financial Leverage (Assets/Equity) ×	1.61	1.93	2.39	2.78	2.57
ROE (5-step product, year-end total equity) %	17.46	9.90	-8.16	-10.86	3.13
ROE (owners' profit / average owners' equity) %	13.83	9.21	-6.92	-9.70	-9.70

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.